Skip to main content

MEIP

Stock
Health Care
Biotechnology

Performance overview

MEIP Price
Price Chart

Forward-looking statistics

Beta
0.48
Risk
46.08%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.

Company info

SectorHealth Care
IndustryBiotechnology
Employees86
Market cap$19.1M

Fundamentals

Enterprise value-$4.0M
Revenue$65.3M
Revenue per employee
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$4.75
Dividend per share
Revenue per share$9.80
Avg trading volume (30 day)$68K
Avg trading volume (10 day)$162K
Put-call ratio

Macro factor sensitivity

Growth+0.0
Credit+6.2
Liquidity-1.0
Inflation-1.2
Commodities-1.0
Interest Rates-3.0

Valuation

Dividend yield0.00%
PEG Ratio-0.72
Price to sales0.27
P/E Ratio-0.72
Enterprise Value to Revenue-0.06
Price to book0.91

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day
Ex. dividend dayNovember 16, 2023

News

MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates

MEI Pharma, Inc. (MEIP) came out with a quarterly loss of $1.66 per share versus the Zacks Consensus Estimate of a loss of $1.46. This compares to earnings of $1.60 per share a year ago.

Zacks Investment Research (February 14, 2024)
Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update

The FDA crushed MEI Pharma Inc's (NASDAQ: MEIP) hopes of winning accelerated approval for its PI3K inhibitor, zandelisib, on the strength of phase 2 data. In the meeting, the FDA informed that a randomized clinical trial is "needed to adequately assess drug efficacy and safety.

Benzinga (March 25, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free